Publication | Closed Access
Phase II Trial of the Anti-G<sub>D2</sub>Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma
204
Citations
34
References
2001
Year
3F8/GM-CSF is well tolerated and shows promise for treatment of minimal residual NB in BM.
| Year | Citations | |
|---|---|---|
Page 1
Page 1